**Author details**

Mona Sadeghalvad1,2,3 and Nima Rezaei1,2,3\*

1 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

3 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

\*Address all correspondence to: rezaei\_nima@tums.ac.ir

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**15**

*Introduction on Monoclonal Antibodies DOI: http://dx.doi.org/10.5772/intechopen.98378*

[1] Forthal DN. Functions of Antibodies. Microbiol Spectr. 2014;2(4):AID-0019- 2014. doi: 10.1128/microbiolspec.

Immunopharmacol. 2020;85:106639. doi:10.1016/j.intimp.2020.106639

[9] Liu YD, Wang T, Chou R, Chen L, Kannan G, Stevenson R, Goetze AM, Jiang XG, Huang G, Dillon TM, Flynn GC. IgG2 disulfide isoform conversion kinetics. Mol Immunol. 2013

Jun;54(2):217-226. doi: 10.1016/j.

[11] Kumar R, Parray HA, Shrivastava T,

[12] Deantonio C, Cotella D, Macor P, Santoro C, Sblattero D. Phage display technology for human monoclonal antibodies. Methods Mol Biol. 2014;1060:277-295. doi: 10.1007/978-

[13] Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol. 2017;13(10):1001-1015. doi: 10.1080/1744666X.2017.1366315.

[14] Foon KA, Yannelli J, Bhattacharya-Chatterjee M. Colorectal cancer as a model for immunotherapy. Clin Cancer Res. 1999 Feb;5(2):225-236. PMID:

immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. Int

[15] Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N. The promising role of monoclonal antibodies for

Sinha S, Luthra K. Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol. 2019 Aug 15;135:907-918. doi: 10.1016/j.ijbiomac.2019.06.006.

[10] Holzlöhner P, Hanack K. Generation of Murine Monoclonal Antibodies by Hybridoma Technology. J Vis Exp. 2017 Jan 2;(119):54832. doi:

molimm.2012.12.005.

10.3791/54832.

1-62703-586-6\_14.

10037169.

[2] Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116. doi:10.1016/j.amsu.

[3] Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi: 10.1186/s12929-019-0592-z.

[4] Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel). 2019;8(4):55. doi:10.3390/antib8040055

[5] Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. Monoclonal Antibodies: A Review. Curr Clin Pharmacol. 2018;13(2):85-99. doi: 10.2174/1574884712666170809124728.

[6] Irani V, Guy AJ, Andrew D,

[7] Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst

future perspectives. Int

Pharmacol. 2017;6(9):576-588. doi:10.1002/psp4.12224.

[8] Parray HA, Shukla S, Samal S, et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and

Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015 Oct;67(2 Pt A):171- 82. doi: 10.1016/j.molimm.2015.03.255.

**References**

properties

2014;09:001
